These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19887796)

  • 1. Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up.
    Cernigliaro C; Sansa M; Vitrella G; Verde A; Bongo AS; Giuliani L; Novelli E
    Cardiology; 2010; 115(1):77-86. PubMed ID: 19887796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation.
    Stojkovic S; Ostojic M; Nedeljkovic M; Stankovic G; Beleslin B; Vukcevic V; Orlic D; Arandjelovic A; Kostic J; Dikic M; Tomasevic M
    Catheter Cardiovasc Interv; 2010 Feb; 75(3):317-25. PubMed ID: 20049961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
    Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G;
    J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
    Waksman R; Ajani AE; Pichard AD; Torguson R; Pinnow E; Canos D; Satler LF; Kent KM; Kuchulakanti P; Pappas C; Gambone L; Weissman N; Abbott MC; Lindsay J;
    J Am Coll Cardiol; 2004 Oct; 44(7):1386-92. PubMed ID: 15464317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
    Hausleiter J; Kastrati A; Mehilli J; Vogeser M; Zohlnhöfer D; Schühlen H; Goos C; Pache J; Dotzer F; Pogatsa-Murray G; Dirschinger J; Heemann U; Schömig A;
    Circulation; 2004 Aug; 110(7):790-5. PubMed ID: 15302787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis.
    Feres F; Muñoz JS; Abizaid A; Albertal M; Mintz GS; Staico R; Centemero M; Mattos LA; Maldonado G; Tanajura LF; Chaves A; Pinto I; Abizaid AS; Seixas AC; Vaz VD; Sousa A; Sousa JE
    Am J Cardiol; 2005 Dec; 96(12):1656-62. PubMed ID: 16360353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions.
    Suttorp MJ; Laarman GJ; Rahel BM; Kelder JC; Bosschaert MA; Kiemeneij F; Ten Berg JM; Bal ET; Rensing BJ; Eefting FD; Mast EG
    Circulation; 2006 Aug; 114(9):921-8. PubMed ID: 16908768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).
    Rodríguez AE; Rodríguez Alemparte M; Vigo CF; Fernández Pereira C; Llauradó C; Vetcher D; Pocovi A; Ambrose J
    Heart; 2005 Nov; 91(11):1433-7. PubMed ID: 15774608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
    Grube E; Sonoda S; Ikeno F; Honda Y; Kar S; Chan C; Gerckens U; Lansky AJ; Fitzgerald PJ
    Circulation; 2004 May; 109(18):2168-71. PubMed ID: 15123533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: a serial intravascular ultrasound study.
    Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Feres F; Staico R; Centemero M; Tanajura LF; Abizaid AC; Rodrigues A; Paes A; Mintz GS; Sousa JE
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):535-40. PubMed ID: 16283682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound.
    Serruys PW; Foley DP; Pieper M; Kleijne JA; de Feyter PJ;
    Eur Heart J; 2001 Oct; 22(20):1938-47. PubMed ID: 11601838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
    Maresta A; Balducelli M; Latini R; Bernardi G; Moccetti T; Sosa C; Barlera S; Varani E; Ribeiro da Silva EE; Monici Preti A; Maggioni AP;
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):375-82. PubMed ID: 15736248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
    Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.
    Popma JJ; Leon MB; Moses JW; Holmes DR; Cox N; Fitzpatrick M; Douglas J; Lambert C; Mooney M; Yakubov S; Kuntz RE;
    Circulation; 2004 Dec; 110(25):3773-80. PubMed ID: 15596568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy).
    Ortolani P; Ardissino D; Cavallini C; Bramucci E; Indolfi C; Aquilina M; Marzocchi A
    Am J Cardiol; 2005 Nov; 96(10):1393-8. PubMed ID: 16275185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.
    Holmes DR; Teirstein P; Satler L; Sketch M; O'Malley J; Popma JJ; Kuntz RE; Fitzgerald PJ; Wang H; Caramanica E; Cohen SA;
    JAMA; 2006 Mar; 295(11):1264-73. PubMed ID: 16531619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial.
    Bestehorn HP; Neumann FJ; Büttner HJ; Betz P; Stürzenhofecker P; von Hodenberg E; Verdun A; Levai L; Monassier JP; Roskamm H
    J Am Coll Cardiol; 2004 Jun; 43(12):2160-5. PubMed ID: 15193674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.
    Fajadet J; Wijns W; Laarman GJ; Kuck KH; Ormiston J; Münzel T; Popma JJ; Fitzgerald PJ; Bonan R; Kuntz RE;
    Minerva Cardioangiol; 2007 Feb; 55(1):1-18. PubMed ID: 17287679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral rapamycin to prevent human coronary stent restenosis: a pilot study.
    Guarda E; Marchant E; Fajuri A; Martínez A; Morán S; Mendez M; Uriarte P; Valenzuela E; Lazen R
    Am Heart J; 2004 Aug; 148(2):e9. PubMed ID: 15309012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.